The primary objective of this study is to evaluate the safety and tolerability of BGT007H cell therapy in patients with recurrent/refractory pancreatic cancer.
voluntarily sign an informed consent form in writing.
Age ≥18 years and ≤75 years, both male and female are eligible.
Expected survival ≥ 3 months.
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
Has active central nervous system (CNS) metastasis (except for those treated and stable).
HIV positive, HBsAg positive with positive Hepatitis B virus (HBV) DNA copy number (greater than the lower limit of detection), Hepatitis C virus (HCV) antibody positive and HCV RNA positive, syphilis non-treponemal antibody (RPR or TRUST) positive.
Has a mental or psychological disorder that cannot cooperate with treatment and efficacy evaluation.
Subjects with severe autoimmune diseases who have been long-term users of immunosuppressants.